This article is more than 5 years old. Information may no longer be current.

Takeda selling Xiidra to Novartis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Takeda Pharmaceutical has entered into an agreement to sell Xiidra to Novartis for up to $5.3 billion.

The sale will enable Takeda to focus on its key business areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience, according to a company press release.

Xiidra (lifitegrast ophthalmic solution 5%) is the only prescription treatment approved by the FDA for signs and symptoms of dry eye disease.

Takeda will receive $3.4 billion upfront in cash and up to an additional $1.9 billion in milestone payments from Novartis, the release said.

In addition, Takeda will sell the TachoSil fibrin sealant patch to Ethicon for approximately $400 million upfront in cash.